Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes Body Care Children Complications Defeat Diabetes Foundation Drugs Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research    » Alternative Medicine    » Beta Cells    » Cause    » Cells    » Children    » Complications    » Control    » Cure    » Diagnosis    » Drugs    » Elderly    » Genes    » Immune Cells    » Inhaled Insulin    » Insulin    » Islet Cells    » Neuropathy    » Obesity    » Oral Insulin    » Other Diseases    » Pets    » Pre-Diabetes    » Prevention    » Research    » Retinopathy    » Risk Factors    » Stem Cells    » Technology    » Testing    » Transplants    » Treatments    » Trials    » Type 1    » Type 2 Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

Research » Drugs

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

DDP-4 inhibitors: A New Class of Oral Antidiabetic Drugs – Coming Soon Posted: Thursday, September 21, 2006

Data emerging on the safety and efficacy of the new oral antidiabetic agents were presented at the European Association for the Study of Diabetes 2006 Meeting.

MannKind Inhaled Insulin Matches Injections -Study Posted: Thursday, September 21, 2006

An inhaled insulin being developed by MannKind Corp produces comparable improvements in blood sugar control to rapid-acting insulin analog (RAA) given by injection, researchers said on Saturday.

Pioglitazone Demonstrates Significant Improvements in Cardiovascular Outcomes Posted: Thursday, September 21, 2006

Actos® (pioglitazone HCl), an oral antidiabetic medication, demonstrated significant cardiovascular benefits in reducing the risk of heart attack and/or stroke and acute coronary syndrome in patients with type 2 diabetes.

New Positive Data On Levemir, NovoRapid Posted: Thursday, September 21, 2006

Levemir improves glucose control without weight gain and hypoglycemia.

A Mid-Summer’s Night DREAM: Diabetes Prevention (Part 2- Ramipril Arm) Posted: Thursday, September 21, 2006

The Dream Study also found that the ACE-inhibitor Altace (ramipril) does not prevent type 2 diabetes in patients with impaired glucose metabolism.

A Mid-Summer’s Night DREAM: Diabetes Prevention (Part 1-Rosiglitazone Arm) Posted: Thursday, September 21, 2006

The results of a major study released: The Dream Study (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) with over 5000 patients Rosiglitazone reduced the risk of developing type 2 diabetes by 62 percent (p<0.0001) relative to placebo among people at high risk of developing type 2 diabetes.

Significant Glucose-Lowering Efficacy Of JANUVIA™ in Phase III Study Posted: Thursday, September 21, 2006

New data presented for the first time at the 42nd annual meeting of the European Association for the Study of Diabetes (EASD) in Copenhagen demonstrated a mean reduction in A1C of 2.1% from a mean baseline A1C of 8.8% and a reduction of 2.9% for those with a mean A1c of 11.2%.

New Hypertension Pills Cut Diabetes Risk by A Third Posted: Thursday, September 21, 2006

Researchers have reported that patients given a specific combination of new blood pressure drugs are one-third less likely to develop diabetes than those on older pills.

Galvus® Demonstrates Powerful Blood Sugar Reductions In Phase III Studies Posted: Thursday, September 21, 2006

Galvus dropped A1c by 1.8% without weight gain.

Steroids Trial Beats Diabetes Blindness Posted: Wednesday, September 13, 2006

Australian research has proven the effectiveness of a steroid treatment for a type of diabetic blindness.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.